Guided Therapeutics (GTHP) Return on Capital Employed (2012 - 2026)
Guided Therapeutics (GTHP) posted Return on Capital Employed of 42.95% for Q4 2025, up 8.52% sequentially from 39.58% in Q3 2025, and down 61.0% YoY from 110.13% in Q4 2024.
Guided Therapeutics (GTHP) Return on Capital Employed (2012 - 2026) Analysis & Trends
Guided Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 42.95% in Q4 2025.
- Quarterly Return on Capital Employed fell 61.0% year-over-year to 42.95% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 42.95% (down 61.0% YoY) and the FY2025 annual result came in at 44.88%, down 63.0% from the prior year.
- Return on Capital Employed climbed to 42.95% in Q4 2025 per GTHP's latest filing, from 39.58% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 427.0% in Q1 2023 and troughed at 22.15% in Q1 2021.
- A 5-year average of 97.87% and a median of 55.27% in 2021 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed soared 36926 bps in 2023, then sank 34797 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 60.65% in 2021, then soared by 339 bps to 266.45% in 2022, then plunged by 57 bps to 113.83% in 2023, then tumbled by 62 bps to 43.56% in 2024, then decreased by 1 bps to 42.95% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 42.95%, 39.58%, and 41.89% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.08% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | 41.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.62% |
| Dec 31, 2025 | 42.95% |
| Sep 30, 2025 | 39.58% |
| Jun 30, 2025 | 41.89% |
| Mar 31, 2025 | 45.78% |
| Dec 31, 2024 | 43.56% |
| Sep 30, 2024 | 43.14% |
| Jun 30, 2024 | 48.68% |
| Mar 31, 2024 | 79.03% |
| Dec 31, 2023 | 113.83% |
| Sep 30, 2023 | 144.00% |
| Jun 30, 2023 | 195.16% |
| Mar 31, 2023 | 427.00% |
| Dec 31, 2022 | 266.45% |
| Sep 30, 2022 | 114.64% |
| Jun 30, 2022 | 50.16% |
| Mar 31, 2022 | 57.74% |
| Dec 31, 2021 | 60.65% |
| Sep 30, 2021 | 68.10% |
| Jun 30, 2021 | 52.80% |